US Patent

US11026931 — Methods for the administration of certain VMAT2 inhibitors

Method of Use · Assigned to Neurocrine Biosciences Inc · Expires 2039-08-14 · 13y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods for administering the VMAT2 inhibitor valbenazine to patients in need thereof.

USPTO Abstract

Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof.

Drugs covered by this patent

valbenazine-tosylate (VALBENAZINE TOSYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1995`	—	valbenazine-tosylate
`U-1995`	—	valbenazine-tosylate
`U-1995`	—	valbenazine-tosylate
`U-1995`	—	valbenazine-tosylate
`U-1995`	—	valbenazine-tosylate
`U-1995`	—	valbenazine-tosylate

Patent Metadata

Patent number: US11026931
Jurisdiction: US
Classification: Method of Use
Expires: 2039-08-14
Drug substance claim: No
Drug product claim: No
Assignee: Neurocrine Biosciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.